| Multiplex genome engineering using CRISPR/Cas systems L Cong, FA Ran, D Cox, S Lin, R Barretto, N Habib, PD Hsu, X Wu, ... Science, 1231143, 2013 | 15888 | 2013 |
| RNA-guided editing of bacterial genomes using CRISPR-Cas systems W Jiang, D Bikard, D Cox, F Zhang, LA Marraffini Nature biotechnology 31 (3), 233, 2013 | 2692 | 2013 |
| C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector OO Abudayyeh, JS Gootenberg, S Konermann, J Joung, IM Slaymaker, ... Science 353 (6299), aaf5573, 2016 | 1699 | 2016 |
| Crispr Evolution: C2c2 is a single-component programmable Rna-guided Rna-targeting Crispr effector OO Abudayyeh, JS Gootenberg, S Konermann, J Joung, IM Slaymaker, ... Science 353 (6299), 557, 2016 | 1699* | 2016 |
| RNA targeting with CRISPR–Cas13 OO Abudayyeh, JS Gootenberg, P Essletzbichler, S Han, J Joung, ... Nature 550 (7675), 280, 2017 | 1407 | 2017 |
| RNA editing with CRISPR-Cas13 DBT Cox, JS Gootenberg, OO Abudayyeh, B Franklin, MJ Kellner, J Joung, ... Science 358 (6366), 1019-1027, 2017 | 1349 | 2017 |
| Therapeutic genome editing: prospects and challenges DBT Cox, RJ Platt, F Zhang Nature medicine 21 (2), 121, 2015 | 1239 | 2015 |
| Diversity and evolution of class 2 CRISPR–Cas systems S Shmakov, A Smargon, D Scott, D Cox, N Pyzocha, W Yan, ... Nature Reviews Microbiology 15 (3), 169, 2017 | 857 | 2017 |
| Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28 AA Smargon, DBT Cox, NK Pyzocha, K Zheng, IM Slaymaker, ... Molecular cell 65 (4), 618-630. e7, 2017 | 471 | 2017 |
| Engineered Cpf1 variants with altered PAM specificities L Gao, DBT Cox, WX Yan, JC Manteiga, MW Schneider, T Yamano, ... Nature biotechnology 35 (8), 789, 2017 | 388 | 2017 |
| CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus V Ramanan, A Shlomai, DBT Cox, RE Schwartz, E Michailidis, A Bhatta, ... Scientific reports 5, 10833, 2015 | 289 | 2015 |
| Crispr-cas component systems, methods and compositions for sequence manipulation F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang, NE Sanjana US Patent 9,822,372, 2017 | 186 | 2017 |
| Crispr-cas component systems, methods and compositions for sequence manipulation F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang, NE Sanjana US Patent App. 15/887,377, 2018 | 105 | 2018 |
| CRISPR-assisted editing of bacterial genomes W Jiang, D Bikard, D Cox, F Zhang, LA Marraffini Nature biotechnology 31 (3), 233, 2013 | 97 | 2013 |
| Engineering and optimising deaminase fusions for genome editing L Yang, AW Briggs, WL Chew, P Mali, M Guell, J Aach, DB Goodman, ... Nature communications 7, 13330, 2016 | 87 | 2016 |
| Engineered Cpf1 Enzymes with Altered PAM Specificities L Gao, DBT Cox, WX Yan, J Manteiga, M Schneider, T Yamano, ... bioRxiv, 091611, 2016 | 20 | 2016 |
| DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) DBT Cox, JE Dahlman, F Zhang US Patent App. 15/619,737, 2017 | 8 | 2017 |
| Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders S Bhatia, C Rice, F Zhang, DBT Cox, V Ramanan, R Schwartz, A Shlomai US Patent App. 15/179,938, 2016 | 8 | 2016 |
| Corrigendum: Engineering and optimising deaminase fusions for genome editing L Yang, AW Briggs, WL Chew, P Mali, M Guell, J Aach, DB Goodman, ... Nature communications 8, 16169, 2017 | 3 | 2017 |
| Novel crispr enzymes and systems F Zhang, A Smargon, N Pyzocha, DBT Cox, ES Lander US Patent App. 15/960,064, 2019 | 2 | 2019 |
